Cannabis extract treatment for terminal acute lymphoblastic leukemia with a Philadelphia chromosome mutation.
Case Rep Oncol. 2013 Nov 28;6(3):585-92. doi: 10.1159/000356446. eCollection 2013.
Abstract
Acute
lymphoblastic leukemia (ALL) is a cancer of the white blood cells and
is typically well treated with combination chemotherapy, with a
remission state after 5 years of 94% in children and 30-40% in adults.
To establish how aggressive the disease is, further chromosome testing
is required to determine whether the cancer is myeloblastic and involves
neutrophils, eosinophils or basophils, or lymphoblastic involving B or T
lymphocytes. This case study is on a 14-year-old patient diagnosed with
a very aggressive form of ALL (positive for the Philadelphia chromosome
mutation). A standard bone marrow transplant, aggressive chemotherapy
and radiation therapy were revoked, with treatment being deemed a
failure after 34 months. Without any other solutions provided by
conventional approaches aside from palliation, the family administered
cannabinoid extracts orally to the patient. Cannabinoid resin extract is
used as an effective treatment for ALL with a positive Philadelphia
chromosome mutation and indications of dose-dependent disease control.
The clinical observation in this study revealed a rapid dose-dependent
correlation.
